TriangleRuxolitinib (NCT06345495)
Ruxolitinib trial for Splenomegaly (NCT06345495). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–75 with primary or secondary myelofibrosis, an enlarged spleen and a fully matched stem-cell donor. Prior JAK-inhibitor treatment is allowed.
The idea: oral ruxolitinib blocks JAK1/2 signaling. Researchers combine it with intravenous busulfan before donor transplantation to study spleen reduction and transplant outcomes. Other transplant medicines are included. They assess blood-cell recovery, graft function, survival and side effects; the record does not publish drug doses.
This phase 2 study plans 30 patients. Uday Popat leads it at MD Anderson in Houston, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.